Skip to main content

21-05-2021 | Oncology | News | Article

News in brief

Durable benefit with atezolizumab in some advanced urothelial cancer patients

Author: Hannah Kitt

medwireNews: Updated results from the phase 3 IMvigor211 trial indicate that some patients with advanced urothelial cancer may derive a long-term benefit from atezolizumab after progression on platinum-based chemotherapy.

As previously reported by medwireNews, the primary analysis of the randomized controlled trial did not show a significant improvement in overall survival (OS) with atezolizumab (n=467) versus physician’s choice of single-agent chemotherapy (n=464).

However, at a median follow-up of 33 months, the OS rate at 24 months was 23% for the atezolizumab group and 13% for the chemotherapy group, with corresponding rates at 30 months of 18% and 10%.

The results were similar in subgroup analyses by PD-L1 expression levels on tumor-infiltrating immune cells, with numerically higher 24- and 30-month OS rates with atezolizumab than chemotherapy among patients with expression levels of less than 1% (23 vs 11% and 18 vs 9%, respectively), those with levels of 1% or more (22 vs 14% and 18 vs 10%), and those with levels of at least 5% (33 vs 18% and 29 vs 17%).

“Safety findings were consistent with the primary analysis, with no new signals detected,” write Michiel van der Heijden (Netherlands Cancer Institute, Amsterdam) and co-investigators.

They conclude in European Urology: “Our findings suggest the potential for long-term survival in this setting and support the recommended use of atezolizumab in prior platinum-treated patients with [metastatic urothelial carcinoma] regardless of PD-L1 status.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

Eur Urol 2021; doi:10.1016/j.eururo.2021.03.024

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage